Castle Biosciences
CSTL
About: Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Employees: 798
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
450% more call options, than puts
Call options by funds: $22K | Put options by funds: $4K
59% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 44
1.17% more ownership
Funds ownership: 90.74% [Q1] → 91.91% (+1.17%) [Q2]
5% more capital invested
Capital invested by funds: $516M [Q1] → $542M (+$25.5M) [Q2]
16% less funds holding
Funds holding: 180 [Q1] → 152 (-28) [Q2]
62% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 42
100% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 0 (-2) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
Canaccord Genuity
Kyle Mikson
|
$37
|
Buy
Maintained
|
9 Sep 2025 |
Financial journalist opinion
Based on 4 articles about CSTL published over the past 30 days
